SCHEMBL23856900

SCHEMBL23856900

CCOC(=O)C1Cc2c(F)cnc(C)c2C1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.39
KMT2A Q03164 5/20 0.39
KDM4E B2RXH2 4/20 0.39
TDP1 Q9NUW8 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
POLB P06746 2/20 0.38
TSHR P16473 1/20 0.38
LIMK1 P53667 1/20 0.37
MAPK1 P28482 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CYP11B2 P19099 1/20 0.36
MEN1 O00255 2/20 0.36
GAA P10253 2/20 0.36
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30046792 1.00 ALDH1A1 (0.39) ALDH1A1KMT2AKDM4ETDP1SMN1; SMN2
SCHEMBL23856546 0.86 KDM4E (0.40) ALDH1A1KMT2AKDM4ETDP1SMN1; SMN2
SCHEMBL30047006 0.86 KDM4E (0.40) ALDH1A1KMT2AKDM4ETDP1SMN1; SMN2
SCHEMBL30047239 0.82 ALDH1A1 (0.50) ALDH1A1KMT2AKDM4ETDP1SMN1; SMN2
SCHEMBL23857269 0.82 ALDH1A1 (0.50) ALDH1A1KMT2AKDM4ETDP1SMN1; SMN2
SCHEMBL23857695 0.81 KMT2A (0.42) ALDH1A1KMT2AKDM4ETDP1SMN1; SMN2
SCHEMBL23856654 0.81 ALDH1A1 (0.38) ALDH1A1KMT2AKDM4ETDP1SMN1; SMN2
SCHEMBL30047338 0.81 KMT2A (0.42) ALDH1A1KMT2AKDM4ETDP1SMN1; SMN2
SCHEMBL23856968 0.80 DGAT1 (0.38) KMT2AKDM4ETSHRNPSR1HPGD
SCHEMBL23857566 0.80 ABL1 (0.32) ALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4126855-B1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS HOFFMANN LA ROCHE (CH) 2024-04-24 EP disclosed
US-20230167127-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION HOFFMANN-LA ROCHE INC. (US) 2023-06-01 US disclosed
US-20230167127-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION HOFFMANN-LA ROCHE INC. (US) 2023-06-01 US disclosed
US-20230167127-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION HOFFMANN-LA ROCHE INC. (US) 2023-06-01 US disclosed
EP-4126855-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION F. Hoffmann-La Roche AG (CH) 2023-02-08 EP disclosed
CN-115298176-A Compounds and their use in the treatment of bacterial infections 豪夫迈·罗氏有限公司 2022-11-04 CN disclosed
WO-2021190727-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2021-09-30 WO disclosed
WO-2021190727-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2021-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167127-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION LTB4R, C5, C3AR1 ALDH1A1 842/4885KMT2A 3563/4885KDM4E 4195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.